PRA Health Sciences Inc (PRAH):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:PRA Health Sciences Inc (PRAH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3336
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PRA Health Sciences Inc (PRA) is a contract research organization (CRO) which provides clinical development services. The company offers services such as phase I-IV study management, and embedded and functional outsourcing services. It offers solutions in bioanalytical laboratories, biometrics, clinical pharmacology, strategic solutions, post-marketing research, clinical diagnostics, and safety and risk management. PRA spans its expertise in the therapeutic areas of biosimilars, oncology, hematology, respiratory, rare diseases, neurology, infectious diseases, cardio-metabolic and immunology. It caters to pharmaceutical and biotechnology industries. The company has presence in the US, Hong Kong, Russia, India, France, Italy, China, Japan, South Africa, Israel and Colombia among others. PRA is headquartered in Raleigh, North Carolina, the US.

PRA Health Sciences Inc (PRAH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
PRA Health Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
PRA Health Sciences Inc, Medical Devices Deals, 2012 to YTD 2018 10
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deal Details 12
Private Equity 12
KKR Completes Acquisition Of PRA International From Genstar Capital 12
KKR Completes Acquisition Of ReSearch Pharma Services From Warburg Pincus 14
Partnerships 16
Care Innovations Enters into Partnership with PRA Health Sciences 16
Delmar Pharma Enters into Agreement with PRA Health Sciences 17
PRA Health Sciences and Takeda Pharma Form Joint Venture 18
PRA Health Sciences Enters into Agreement with Takeda Pharma 19
PRA Health Sciences Enters into Agreement with Alliance for Multispecialty Research 20
ReSearch Pharma Forms Joint Venture With Asklep 21
WuXi PharmaTech To Form Joint Venture With PRA International 22
Equity Offering 23
PRA Health Sciences Prices Public Offering of Shares 23
PRA Health Sciences Raises USD416.3 Million in Public Offering of Shares 25
PRA Health Sciences Raises USD234 Million in Public Offering of Shares 27
PRA Health Sciences Raises USD211.3 Million in Public Offering of Shares 28
PRA Health Sciences Completes IPO for USD351.4 Million 29
Acquisition 31
PRA International Acquires CRI Lifetree For USD77.1 Million 31
PRA Health Sciences Acquires ReSearch Pharma 32
PRA International Acquires ClinStar 33
PRA Health Sciences Inc – Key Competitors 34
PRA Health Sciences Inc – Key Employees 35
PRA Health Sciences Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Joint Venture 38
Recent Developments 39
Strategy And Business Planning 39
Jan 16, 2018: PRA Health Sciences Opens New Salt Lake City Clinic 39
Financial Announcements 40
Aug 01, 2018: PRA Health Sciences reports second quarter 2018 results and updates full year 2018 guidance 40
Apr 25, 2018: PRA Health Sciences Announces First Quarter 2018 Financial Results 42
Feb 21, 2018: PRA Health Sciences Reports Fourth Quarter 2017 Financial Results 44
Oct 25, 2017: PRA Health Sciences Reports Third Quarter 2017 Results and Updates Full Year 2017 Guidance 46
Aug 07, 2017: PRA Health Sciences Reports Second Quarter 2017 Results and Updates Full Year 2017 Guidance 48
Apr 25, 2017: PRA Health Sciences Reports First Quarter 2017 Results 50
Feb 22, 2017: PRA Health Sciences Reports Fourth Quarter and Full Year 2016 Results and Provides Q1 and Full Year 2017 Guidance 52
Corporate Communications 54
Apr 25, 2018: PRA Health Sciences Announces Senior Management Changes 54
Aug 14, 2017: PRA Health Sciences Announces Appointment of New Director 55
Government and Public Interest 56
Mar 27, 2018: Leading CROs Form New Industry Standards Group to Improve Collaboration with Sponsors 56
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
PRA Health Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
PRA Health Sciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9
PRA Health Sciences Inc, Medical Devices Deals, 2012 to YTD 2018 10
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
KKR Completes Acquisition Of PRA International From Genstar Capital 12
KKR Completes Acquisition Of ReSearch Pharma Services From Warburg Pincus 14
Care Innovations Enters into Partnership with PRA Health Sciences 16
Delmar Pharma Enters into Agreement with PRA Health Sciences 17
PRA Health Sciences and Takeda Pharma Form Joint Venture 18
PRA Health Sciences Enters into Agreement with Takeda Pharma 19
PRA Health Sciences Enters into Agreement with Alliance for Multispecialty Research 20
ReSearch Pharma Forms Joint Venture With Asklep 21
WuXi PharmaTech To Form Joint Venture With PRA International 22
PRA Health Sciences Prices Public Offering of Shares 23
PRA Health Sciences Raises USD416.3 Million in Public Offering of Shares 25
PRA Health Sciences Raises USD234 Million in Public Offering of Shares 27
PRA Health Sciences Raises USD211.3 Million in Public Offering of Shares 28
PRA Health Sciences Completes IPO for USD351.4 Million 29
PRA International Acquires CRI Lifetree For USD77.1 Million 31
PRA Health Sciences Acquires ReSearch Pharma 32
PRA International Acquires ClinStar 33
PRA Health Sciences Inc, Key Competitors 34
PRA Health Sciences Inc, Key Employees 35
PRA Health Sciences Inc, Other Locations 36
PRA Health Sciences Inc, Subsidiaries 37
PRA Health Sciences Inc, Joint Venture 38

List of Figures
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
PRA Health Sciences Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[PRA Health Sciences Inc (PRAH):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bank of Nanjing Co., Ltd.:戦略・SWOT・企業財務分析
    Bank of Nanjing Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Bank of Nanjing Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • AVEO Pharmaceuticals Inc (AVEO):製薬・医療:M&Aディール及び事業提携情報
    Summary AVEO Pharmaceuticals Inc (AVEO) is a biopharmaceutical company which focuses on the discovery, development and commercialization of drugs for the treatment of various types of cancers. Its proprietary platform delivers insights into cancer and related diseases. AVEO develops its lead candida …
  • Canada Energy Partners Inc (CE):石油・ガス:M&Aディール及び事業提携情報
    Summary Canada Energy Partners Inc (Canada Energy) is a natural gas exploration and development company. The company concentrates on mid-stream supplying of water disposal services, development of a wellbore mining technology and energy or mineral exploring. It develops a wellbore mining technology …
  • Sam’s West Inc:企業の戦略的SWOT分析
    Sam's West Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • American Greetings Corporation (AM):企業の戦略的SWOT分析
    American Greetings Corporation (AM) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Duke Energy Corporation:企業の戦略・SWOT・財務情報
    Duke Energy Corporation - Strategy, SWOT and Corporate Finance Report Summary Duke Energy Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Unilever Pakistan Limited:企業の戦略・SWOT・財務情報
    Unilever Pakistan Limited - Strategy, SWOT and Corporate Finance Report Summary Unilever Pakistan Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Traverse Biosciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Traverse Biosciences Inc (Traverse Biosciences) is an independent bioscience company that commercializes drug candidates for the treatment of inflammatory diseases and age-related conditions affecting humans and companion animals. The company’s lead candidate TRB-N0224 is developed for canin …
  • Avista Corporation
    Avista Corporation - Strategy, SWOT and Corporate Finance Report Summary Avista Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Katara Hospitality:企業の戦略・SWOT・財務分析
    Katara Hospitality - Strategy, SWOT and Corporate Finance Report Summary Katara Hospitality - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Biogen Inc (BIIB):企業の財務・戦略的SWOT分析
    Biogen Inc (BIIB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Korab Resources Ltd (KOR):企業の財務・戦略的SWOT分析
    Summary Korab Resources Ltd (Korab) is a mining exploration company. The company’s business activities include evaluation, exploration, acquisition, production, and development of mineral resource properties. It explores for gold, potash, silver, tin, copper, rare earths, nickel, lead, zinc, magnesi …
  • Versartis Inc (VSAR):製薬・医療:M&Aディール及び事業提携情報
    Summary Versartis Inc (Versartis) is a biopharmaceutical company that develops, manufactures and commercializes medicines for the treatment of endocrine disorders. The company’s lead product candidate include somavaratan (VRS-317) is a recombinant human growth hormone (GHD) that is designed to reduc …
  • Cesca Therapeutics Inc (KOOL)-医療機器分野:企業M&A・提携分析
    Summary Cesca Therapeutics Inc (Cesca) researches, develops, and commercializes cell based therapeutics for applications in regenerative medicine. Its proprietary technology platform, PXP is used to develop autologous cell-based therapies for the in the vascular and orthopedic markets. Its device di …
  • Jerusalem Insurance Company PLC:企業の戦略・SWOT・財務情報
    Jerusalem Insurance Company PLC - Strategy, SWOT and Corporate Finance Report Summary Jerusalem Insurance Company PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • The North West Company Inc. (NWC):企業の財務・戦略的SWOT分析
    The North West Company Inc. (NWC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Barrick Gold Corporation:戦略・SWOT・企業財務分析
    Barrick Gold Corporation - Strategy, SWOT and Corporate Finance Report Summary Barrick Gold Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • AviChina Industry & Technology Co., Ltd. (2357):企業の財務・戦略的SWOT分析
    AviChina Industry & Technology Co., Ltd. (2357) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • Estel Technologies Pvt. Ltd:企業の戦略的SWOT分析
    Estel Technologies Pvt. Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Active Motif Inc:医療機器:M&Aディール及び事業提携情報
    Summary Active Motif Inc (Active Motif) is a healthcare company that develops and delivers biological research tools. The company’s products include extracts, antibodies, reporter assays, fluorescent dyes, kits, cell, acid, and tissue extracts, molecules and recombinant proteins, among others. It of …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆